Needle-Free Injection System: SII to acquire 20% stake in IntegriMedical

Needle-Free Injection System: Serum Institute of India (SII) has announced a strategic investment in IntegriMedical. As part of the investment, the world's largest vaccine manufacturer will acquire a 20 per cent stake in the company. The partnership is aimed at advancing needle-free injection system technology in India.

IntegriMedical has developed a US patented Needle-Free Injection System (N-FIS) that utilizes high-velocity jet stream using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience.

"IntegriMedical's N-FIS represents a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionize the way we administer vaccines, making the process more comfortable for patients and healthcare professionals," SII CEO Adar Poonawalla said.

"We are excited to have Serum Institute of India as our strategic partner," said Sarvesh Mutha, MD, IntegriMedical. 

IntegriMedical’s Needle-Free Injections System also known as N-FIS has received regulatory approvals from CDSCO, CE, MDSAP and is ISO 13485 certified. Additionally, the technology is patented in the United States. IntegriMedical's MD, Ankur Naik, has been instrumental in the development and clinical trials of the N-FIS technology, demonstrating its effectiveness in reducing pain and eliminating needle-phobia in patients.